This study will determine the efficacy, safety, and tolerability of AMG 162 in the treatment of Rheumatoid Arthritis (RA).

Condition	Treatment or Intervention	Phase
Rheumatoid Arthritis	Drug: AMG 162	Phase II

Further Study Details: 

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Diagnosis of RA
• All subjects will be required to have been taking a stable dose of methotrexate
• Active RA at screening defined as greater than or equal to 6 swollen joints
• The presence of erosive disease

Exclusion Criteria:

• Received any biologic agent (e.g., Enbrel®, Remicade®, Humira®, Kineret®) or Arava® within 8 weeks before randomization; past use of these agents is allowed
• Steroid use greater than 15 mg/day
• Scheduled for surgery or joint replacement in the hands, wrists or feet

Amgen Call Center      866-572-6436 

Alabama
      Research Site, Birmingham,  Alabama,  United States; Recruiting
      Research Site, Huntsville,  Alabama,  United States; Recruiting
      Research Site, Mobile,  Alabama,  United States; Recruiting
Arizona
      Research Site, Glendale,  Arizona,  United States; Recruiting
      Research Site, Tucson,  Arizona,  United States; Recruiting
California
      Research Site, Anaheim,  California,  United States; Recruiting
      Research Site, La Jolla,  California,  United States; Recruiting
      Research Site, Sacramento,  California,  United States; Recruiting
      Research Site, San Diego,  California,  United States; Recruiting
      Research Site, Tarzana,  California,  United States; Recruiting
Colorado
      Research Site, Denver,  Colorado,  United States; Recruiting
Florida
      Research Site, Daytona Beach,  Florida,  United States; Recruiting
      Research Site, Ocala,  Florida,  United States; Recruiting
      Research Site, Orlando,  Florida,  United States; Recruiting
      Research Site, Port Orange,  Florida,  United States; Recruiting
Georgia
      Research Site, Atlanta,  Georgia,  United States; Recruiting
Illinois
      Research Site, Springfield,  Illinois,  United States; Recruiting
Massachusetts
      Research Site, Boston,  Massachusetts,  United States; Recruiting
Nebraska
      Research Site, Omaha,  Nebraska,  United States; Recruiting
New Jersey
      Research Site, Voorhees,  New Jersey,  United States; Recruiting
New York
      Research Site, Smithtown,  New York,  United States; Recruiting
      Research Site, Rochester,  New York,  United States; Recruiting
Ohio
      Research Site, Mayfield Village,  Ohio,  United States; Recruiting
Oklahoma
      Research Site, Tulsa,  Oklahoma,  United States; Recruiting
Oregon
      Research Site, Portland,  Oregon,  United States; Recruiting
Tennessee
      Research Site, Chattanooga,  Tennessee,  United States; Recruiting
Texas
      Research Site, Dallas,  Texas,  United States; Recruiting
Wisconsin
      Research Site, La Crosse,  Wisconsin,  United States; Recruiting

Study ID Numbers:  20040144
Record last reviewed:  February 2005
Last Updated:  February 14, 2005
Record first received:  November 5, 2004
ClinicalTrials.gov Identifier:  NCT00095498
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08